Why is Concord Biotech falling/rising?

As of 19-Aug, Concord Biotech Ltd's stock price is currently at 1,639.65, reflecting an increase of 5.9 points or 0.36%. The stock has been gaining for the last three days, with a total return of 0.9% during this period, and it has outperformed its sector by 0.49% today. However, the stock has experienced a significant decline over the past month, down 13.42%, and a year-to-date drop of 25.81%. Despite a high management efficiency indicated by a return on equity (ROE) of 19.76% and a low debt-to-equity ratio, the company faces challenges such as a 52.6% decline in profit after tax compared to the previous quarter and the lowest net sales recorded at Rs 203.99 crore. Additionally, institutional investors have reduced their stake, which may contribute to the stock's volatility.
In the broader market context, the Sensex has increased by 1.76% over the past week, contrasting with Concord Biotech's minimal gain of 0.03% during the same period. While the stock's recent performance shows some short-term recovery, its long-term growth prospects appear poor, with an operating profit growth rate of only 19.91% over the last five years. The stock's valuation is considered expensive with a price-to-book value of 9.5, and despite a slight uptick in price, the overall sentiment remains cautious due to falling participation from institutional investors and a high PEG ratio of 3.5, indicating potential overvaluation relative to its earnings growth.